Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S, Brunner T, Hinke A, Becker I, Frey B, Semrau S, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Fietkau R. Hecht M, et al. Among authors: eckstein m. J Immunother Cancer. 2020 Oct;8(2):e001378. doi: 10.1136/jitc-2020-001378. J Immunother Cancer. 2020. PMID: 33023982 Free PMC article.
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Eckstein M, et al. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528808
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.
Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany. Pfannstiel C, et al. Among authors: eckstein m. Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15. Cancer Immunol Res. 2019. PMID: 30988029
DAPK1 loss triggers tumor invasion in colorectal tumor cells.
Steinmann S, Kunze P, Hampel C, Eckstein M, Bertram Bramsen J, Muenzner JK, Carlé B, Ndreshkjana B, Kemenes S, Gasparini P, Friedrich O, Andersen C, Geppert C, Wang S, Eyupoglu I, Bäuerle T, Hartmann A, Schneider-Stock R. Steinmann S, et al. Among authors: eckstein m. Cell Death Dis. 2019 Nov 26;10(12):895. doi: 10.1038/s41419-019-2122-z. Cell Death Dis. 2019. PMID: 31772156 Free PMC article.
PD-L1 assessment in urothelial carcinoma: a practical approach.
Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. Eckstein M, et al. Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24. Ann Transl Med. 2019. PMID: 31930091 Free PMC article. Review.
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Göppinger S, Schwamborn K, Hieke-Schulz S, Harlow G, Flores M, Wullich B, Wirth M, Roth W, Knüchel R, Weichert W, Baretton G, Hartmann A. Sommer U, et al. Among authors: eckstein m. Clin Genitourin Cancer. 2020 Oct;18(5):e629-e642. doi: 10.1016/j.clgc.2020.02.009. Epub 2020 Feb 15. Clin Genitourin Cancer. 2020. PMID: 32178978 Free article.
753 results